Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Fig. 1

Progression free survival (PFS) and overall survival (OS) by NER. A) Median PFS was 8.6 mo in the <mNER group (n = 55) vs 3.2 mo in the >mNER group (n = 55) (HR 0.50, p < 0.01). B) Median OS was NR in the <mNER group (n = 55) vs 27.3 mo in the >mNER group (n = 55) (HR 0.31, p < 0.01). C) PFS by NER quartiles: Q1 (n = 28) HR 0.51, p = 0.03; Q2 (n = 27) HR 0.44, p = 0.01; Q3 (n = 28) HR 0.93, p = 0.79); Q4 (n = 27) reference. D) OS by NER quartiles: Q1 (n = 28) HR 0.24, p < 0.01; Q2 (n = 27) HR 0.27, p = 0.01; Q3 (n = 28) HR 0.69, p = 0.35; Q4 (n = 27) reference. Q1 (1st quartile), Q2 (2nd quartile), Q3 (3rd quartile), Q4 (4th quartile)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us